CheckMate-9ER Shows Efficacy of Nivolumab/Cabozantinib Combo in RCC
Bradley McGregor, MD, discusses the CheckMate-9ER trial of nivolumab plus cabozantinib versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma.
Bradley McGregor, MD, clinical director of Lank Center for Genitourinary Oncology, senior physician at Dana-Farber Cancer Institute, and instructor of Medicine at Harvard Medical School, discusses the CheckMate-9ER trial (NCT03141177) of nivolumab (Opdivo) plus cabozantinib (Cabometyx) versus sunitinib (Sutent) in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC).
This trial enrolled patients from all of the International Metastatic RCC Database Consortium risk groups. The number of patients in each risk were comparable to real-world practice according to McGregor, with 20% to 25% having favorable risk, about 60% having intermediate risk, and about 20% having poor risk. The patients were evenly distributed through the United States, Europe, and the rest of the world.
The data from the initial analysis showed that there was a marked improvement in progression-free survival (PFS) at a median follow-up of 18 months. This improvement produced a hazard ratio of 0.51, with a median PFS of 16.6 months with the combination versus 8.3 months with sunitinib. The overall survival has not been reached in either group, but the hazard ratio favors the combination at 0.60. McGregor says the P value was also statistically significant. The subgroups also favored nivolumab and cabozantinib in this study.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
